Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (191-200 of 219) with videos related to

Pageof 22
Sort By:
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Plos One|January 23, 2026
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasisRichard B Warren, Hamish J A Hunter, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
Pageof 22

Showing results (191-200 of 219) with videos related to

Sort By:
Pageof 22
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Plos One|January 23, 2026
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasisRichard B Warren, Hamish J A Hunter, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.
Pageof 22